Overview

AGN-241751 in the Treatment of Major Depressive Disorder

Status:
Completed
Trial end date:
2019-10-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of AGN-241751 in participants with Major Depressive Disorder
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Naurex, Inc, an affiliate of Allergan plc